- Home
- SIGA
as 08-22-2025 4:00pm EST
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 515.1M | IPO Year: | 1997 |
| Target Price: | N/A | AVG Volume (30 days): | 640.7K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | Dividend Payout Frequency: | Annual | |
| EPS: | 1.14 | EPS Growth: | -2.56 |
| 52 Week Low/High: | $4.95 - $9.80 | Next Earning Date: | 08-05-2025 |
| Revenue: | $179,639,422 | Revenue Growth: | 3.86% |
| Revenue Growth (this year): | -10.61% | Revenue Growth (next year): | 95.31% |
Latest SIGA Technologies Inc. News
SIGA Breaking Stock News: Dive into SIGA Ticker-Specific Updates for Smart Investing
Zacks
a month ago
Siga Technologies Inc. (SIGA) Laps the Stock Market: Here's Why
Zacks
2 months ago
Why Siga Technologies Inc. (SIGA) Outpaced the Stock Market Today
Zacks
2 months ago
Here's Why Siga Technologies Inc. (SIGA) Fell More Than Broader Market
Simply Wall St.
2 months ago
Undiscovered Gems In US Market Including SIGA Technologies And 2 Other Small Caps
Zacks
2 months ago
Why Siga Technologies Inc. (SIGA) Dipped More Than Broader Market Today
Simply Wall St.
3 months ago
We Think You Can Look Beyond SIGA Technologies' (NASDAQ:SIGA) Lackluster Earnings
Simply Wall St.
3 months ago
Undiscovered Gems in the US Market for May 2025
Simply Wall St.
3 months ago
SIGA Technologies First Quarter 2025 Earnings: US$0.006 loss per share (vs US$0.14 profit in 1Q 2024)
Compare SIGA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SIGA SIGA Technologies Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.